ReviewExperimental & molecular medicine2025
Multifaceted roles of CARM1 beyond histone arginine methylation.
Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- KDM4A Erases the H3R17me2a Mark, Facilitating Chromosome Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Coactivator-associated arginine methyltransferase 1 (CARM1), first identified in 1999, has been studied primarily for its nuclear role in epigenetic regulation through histone methylation. Subsequent research has expanded the substrate repertoire to include nonhistone proteins, thus uncovering broader functions in maintaining cellular homeostasis by regulating transcription, RNA processing, metabolism and organelle dynamics. More recently, CARM1 was shown to exert scaffolding functions independent of its catalytic activity, thereby orchestrating key signaling events involved in transcriptional activation, replication stress response and cell cycle control. These findings highlight the multifaceted roles of CARM1 in nuclear and cytoplasmic compartments. Despite substantial progress in the development of selective small-molecule inhibitors, their inability to target noncatalytic functions has limited their therapeutic potential. Consequently, novel strategies, such as proteolysis-targeting chimeras, are being explored to degrade the entire CARM1 protein, thereby abolishing its enzymatic and scaffolding functions. Here this review outlines the evolving functional landscape of CARM1, from its roles as a transcriptional coactivator to a multifunctional regulator of cellular homeostasis, with an emphasis on its enzyme-independent functions, thereby providing novel insights for next-generation therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.